Technology
Results: 21421-21432 of 31563

Motive Accelerates Consumer Device Entitlements, Adding Direct-to-Cell (D2C) and 5G Slicing Use-Cases

Athos Announces Positive Topline Phase 1 Data for its AI-Generated, Novel, Oral G9A Inhibitor ATH-063, Demonstrating Selective Expansion and Activation of Potent Anti-Inflammatory Regulatory T Cells







